CDSCO Approves Targeted Breast Cancer Drug Dato-DXd
In News
What Happened
Why It Matters
Background
History & Context
What Changed
- ▶
BEFORE: Metastatic HR-positive, HER2-negative breast cancer patients who exhausted endocrine therapies had to rely primarily on conventional systemic chemotherapy, which causes broad cellular toxicity. NOW: Patients have access to Dato-DXd (Datverzo), a targeted antibody-drug conjugate that selectively delivers a potent topoisomerase I inhibitor directly to TROP2-expressing tumor cells.
- ▶
BEFORE: AstraZeneca had only one approved antibody-drug conjugate in India (trastuzumab deruxtecan) for breast cancer. NOW: Dato-DXd marks the second approved ADC in India for the company, expanding the precision oncology portfolio for a different molecular subtype of breast cancer.
Prelims Angle
NCERT Connection
Practice Questions
Q1
Correct Statement(s)Consider the following statements regarding Datopotamab Deruxtecan (Dato-DXd): 1. It is an antibody-drug conjugate (ADC) that specifically targets the TROP2 antigen found on the surface of certain cancer cells. 2. It delivers a topoisomerase I inhibitor payload to destroy tumor cells while minimizing damage to healthy tissues. Which of the statements given above is/are correct?